Dr. Zhanwu Yu 于占武
Chief Physician
Department of Thoracic Surgery, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lung, esophageal, mediastinal, diaphragmatic, and chest wall tumors. Performs radical surgeries, including uniportal VATS lobectomy, segmentectomy, and thoracoscopic-laparoscopic combined esophagectomy.
Dr. Yu is Deputy Director of Thoracic Surgery, Chief Physician, and Master’s supervisor at Liaoning Cancer Hospital & Institute. Holds a medical doctorate. Completed training at Akita University and Juntendo University in Japan in 2002 and 2007. Publishes medical papers and leads three provincial and one municipal research funds.
Professional roles
- Standing Committee Member, Lung Cancer Professional Committee, Liaoning Anti-Cancer Association
- Member, Youth Committee, Thoracic Surgery Branch, Liaoning Medical Association
- Member, Lung Cancer Professional Committee, Liaoning Life Science Society
- Member, International Association for the Study of Lung Cancer
Name order: in Chinese the family name comes first (Yu Zhanwu). Papers usually list the name as Zhanwu Yu or Yu Z.
Selected publications
28 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Cardiothorac Surg, 2026 (senior author): A novel and simple Inflation-deflation method with inflated targeted segments for confirming the intersegmental border under video-assisted thoracoscopic surgery: a technical note. PubMed 42902303
- Cell Death Dis, 2026 (senior author): Correction: Promotion of stem cell-like phenotype of lung adenocarcinoma by FAM83A via stabilization of ErbB2. PubMed 41927526
- Front Cell Dev Biol, 2026 (senior author): Cancer-associated fibroblast heterogeneity and its role in reshaping immunotherapy in solid cancers: potential strategies and clinical promise. PubMed 41884783
- Cell Death Dis, 2024 (senior author): Promotion of stem cell-like phenotype of lung adenocarcinoma by FAM83A via stabilization of ErbB2. PubMed 38942760
- Spectrochim Acta A Mol Biomol Spectrosc, 2024 (senior author): Detection of lung cancer through SERS analysis of serum. PubMed 38569385
- Cell Cycle, 2020 (first author): LncRNA SBF2-AS1 affects the radiosensitivity of non-small cell lung cancer via modulating microRNA-302a/MBNL3 axis. PubMed 31928130
- J Comp Eff Res, 2019 (first author): Cost-effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China. PubMed 30922074
- Asian Pac J Trop Med, 2015 (first author): Antitumor effect of recombinant human endostatin combined with cisplatin on rats with transplanted Lewis lung cancer. PubMed 26321522
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion